Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace(Cedars-Sinai Medical Center), Caroline Gordon(University of Birmingham), Frédéric Houssiau(Cliniques Universitaires Saint-Luc), Anna Barry(UCB Pharma (United States)), Lexy Kelley(UCB Pharma (United States)), Sabine Bongardt(UCB Pharma (Germany)), B. Kilgallen(UCB Pharma (United States)), Michelle Petri(Johns Hopkins University), Vibeke Strand(Stanford University), Marilyn C. Pike(Bethesda Hospital), Kenneth Kalunian(University of California, San Diego)
Cited by 340
Related Papers
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726